- A new once-a-day pill, Orforglipron, has demonstrated “significant” reductions in body weight, potentially offering a more accessible and cheaper alternative to existing injectable weight-loss medications.
- A study published in the New England Journal of Medicine revealed that almost one in five participants (18.4 per cent) taking the highest dose of Orforglipron lost 20 per cent or more of their body weight over 72 weeks.
- The research, which involved 3,127 participants from various countries, also showed that those on the highest 36mg dose experienced an average weight loss of 11.2 per cent.
- Experts anticipate that the tablet form will simplify obesity treatment and enhance convenience, thereby broadening access to effective weight-loss medications for more individuals.
- In addition to weight loss, patients using Orforglipron saw improvements in blood pressure, waist circumference, and cholesterol levels, with common side effects being mild to moderate gastrointestinal issues.
IN FULL
